Effects of Time-restricted Eating on Nutrient Absorption in Healthy Adults
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
The obesity epidemic is well documented, and despite a complex etiology influenced by genetic, physiological, psychological, social, behavioral, and environmental factors, obesity seems to be the result of energy imbalance, where energy intake exceeds energy expenditure, regardless of the internal and external influences. Studies aiming to quantify and manipulate modulators of energy balance, including gastrointestinal (GI) energy absorption rates (i.e., digestibility), are crucial for reducing the incidence of overweight and obesity and improving overall human health. Despite considerable interindividual variability in the amount of ingested energy that is absorbed (~87-98% of ingested energy) by the gastrointestinal tract, generalized equations are used to calculate individual energy intake requirements, and the factors that contribute to such variability, including meal-timing, are largely unknown.
The proposed study seeks to determine the effects of restricting the eating window to 6-h (early time-restricted eating) as compared to a control eating window of 12 h on energy and macronutrient digestibility, thermic effect of food (TEF), postprandial blood metabolites (triglyceride, insulin, glucose, fructose, galactose, inositol, and sorbitol), 24 h glucose concentrations and glycemic variability, intestinal hydrogen gas production, microbiome composition, and gastrointestinal transit time in response to a controlled, energy balanced diet. In addition, this project will determine whether energy digestibility can be predicted from biological and physiological factors such as gut microbiota composition, gastrointestinal transit time, 24-h glucose concentrations, and postabsorptive and postprandial metabolomic profiles.
Participants will be randomized to early TRE (6-h feeding window, 8am-2pm) or a control eating schedule (12-h feeding window, 8am-8pm) and consume a controlled, energy balance diet (breakfast, lunch, dinner, snacks, and beverages) for 9 consecutive days before crossing over to the other intervention after at least a 3-wk washout for females (to control for hormonal fluctuations) and at least a 2-wk washout for males. Participants will collect stool and urine during each feeding phase. Gross energy content (heat combustion by bomb calorimetry) of the diet, stool, and urine samples will be used to calculate energy digestibility (diet gross energy - stool gross energy) and metabolizable energy. Factors that may mediate and/or predict energy digestibility efficiency, including gastrointestinal microbial composition, transit time, and gas production, fasting and postprandial metabolites, continuous glucose concentrations, and thermogenesis will be assessed.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Florida
-
Tallahassee, Florida, Yhdysvallat, 32306
- Florida State University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- 20-45 years old
- Normal weight or overweight (18.5 to 29.9 kg/m2)
- Not taking any probiotics for 4 weeks prior to and throughout the entire study
- Willing to refrain from smoking, vaping, chewing tobacco, and dietary supplement use throughout the study
- Willing to consume a controlled diet for 9 consecutive days on 2 different occasions (18 days total) and collect all urine and fecal output for 3-5 days during each occasion
- Pass the blue dye gastrointestinal tracer (given at screening) within 72 hours of administration
Exclusion Criteria:
- Metabolic or cardiovascular abnormalities, gastrointestinal disorders, prior bariatric surgery, malabsorption, or any condition that interferes with metabolism (e.g., kidney disease, diabetes, cardiovascular disease, etc.)
- Suspected or known strictures, fistulas, or physiological/mechanical gastrointestinal obstruction
- Present condition of alcoholism, anabolic steroids, or other substance abuse issues
- Women who are pregnant, lactating, planning to become pregnant, or who have an irregular menstrual cycle in the past 6 months
- Weight fluctuations ± 5% of body weight in the last 6 months
- Allergies or intolerance to foods included in the controlled diet
- Any use of antibiotics, except topical antibiotics, within 3 months of study participation
- Colonoscopy within 3 months of study participation
- Use of laxatives, stool softeners, or anti-diarrheal medications more than once a week within 4-weeks of study enrollment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: early time-restricted eating (eTRE)
Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 6-h window in the morning hours (e.g., 8:00 AM - 2:00 PM)
|
A diet meeting the participant's weight maintenance energy needs will be provided.
|
|
Kokeellinen: control eating schedule (CON)
Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 12-h window in the morning hours (e.g., 8:00 AM - 8:00 PM)
|
A diet meeting the participant's weight maintenance energy needs will be provided.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Energy digestibility
Aikaikkuna: Days 4-9
|
Calculated as gross energy of the diet (kcals) - gross energy excreted in stool (kcals)
|
Days 4-9
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Fat digestibility
Aikaikkuna: Days 4-9
|
Calculated as fat content of the diet - fat content excreted in stool
|
Days 4-9
|
|
Carbohydrate digestibility
Aikaikkuna: Days 4-9
|
Calculated as carbohydrate content of the diet - carbohydrate content excreted in stool
|
Days 4-9
|
|
Protein digestibility
Aikaikkuna: Days 4-9
|
Calculated as protein content of the diet - protein content excreted in stool
|
Days 4-9
|
|
Metabolizable energy
Aikaikkuna: Days 4-9
|
Calculated as gross energy of the diet (kcals) - gross energy excreted in urine and stool (kcals)
|
Days 4-9
|
|
Metabolizable protein
Aikaikkuna: Days 4-9
|
Calculated as protein content of the diet - protein excreted in urine and stool
|
Days 4-9
|
|
Postabsorptive and postprandial plasma metabolites
Aikaikkuna: Day 6
|
Plasma metabolites will be measured using gas chromatography coupled with mass spectrometry in the postabsorptive state and following a standardized meal (1 hour, 2 hours, 3 hours, and 4 hours after meal intake).
|
Day 6
|
|
Gut microbiome
Aikaikkuna: Day 6
|
Microbiota composition and diversity will be determined using 16S rRNA gene sequencing.
|
Day 6
|
|
Gastrointestinal transit time
Aikaikkuna: Day 6
|
A gas-sensing capsule will be ingested to measure transit time in the gastrointestinal tract.
|
Day 6
|
|
Gastrointestinal gas production
Aikaikkuna: Day 6
|
A gas-sensing capsule will be ingested to measure hydrogen, carbon dioxide, and oxygen production in the gastrointestinal tract.
|
Day 6
|
|
Gastrointestinal temperature
Aikaikkuna: Day 6
|
A gas-sensing capsule will be ingested to measure temperature in the gastrointestinal tract.
|
Day 6
|
|
24-h glucose concentrations
Aikaikkuna: Days 1-8
|
A continuous glucose monitor will be used to collect and assess 24-h glucose concentrations.
|
Days 1-8
|
|
24-h glucose variability
Aikaikkuna: Days 1-8
|
A continuous glucose monitor will be used to collect and assess 24-h glucose variability.
|
Days 1-8
|
|
Thermic effect of food
Aikaikkuna: Day 6
|
Indirect calorimetry measures will be collected in the resting state and for 4 hours (15-30, 45-60, 75-90, 105-120, 165-180, and 225-240 minutes) following the consumption of a standardized meal.
|
Day 6
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Claire E Berryman, Ph.D., Florida State University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- STUDY00001564
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .